New triple therapy aims to slow advanced lung cancer
NCT ID NCT07355205
First seen Jun 27, 2026 · Last updated Jul 10, 2026 · Updated 2 times
Summary
This study tests a new combination of three drugs (nivolumab, ipilimumab, and nogapendekin alfa inbakicept) for people with stage IV or recurrent non-small cell lung cancer. The goal is to see if this treatment helps keep the cancer from growing longer than standard two-drug therapy. About 26 adults will receive the drugs in 6-week cycles for up to 24 months.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER RECURRENT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Washington University School of Medicine
RECRUITINGSt Louis, Missouri, 63110, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a lung cancer drug designed for one mutation work for another?
- Experimental lung cancer vaccine trial halted early
- New radioactive drug targets Hard-to-Treat cancers in early trial
- New test aims to match lung cancer patients with best therapy
- New hope for frail lung cancer patients: immunotherapy drug tested
- New hope for patients with rare brain lining cancer spread